Gillian M Tozer Selected Research

combretastatin

1/2020	The influence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin A-4-phosphate.
4/2014	MALDI-MSI and label-free LC-ESI-MS/MS shotgun proteomics to investigate protein induction in a murine fibrosarcoma model following treatment with a vascular disrupting agent.
10/2011	Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate.
1/2008	Estimation of apparent tumor vascular permeability from multiphoton fluorescence microscopic images of P22 rat sarcomas in vivo.
2/2007	Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down.
12/2006	Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression.
10/2002	The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses.
7/2002	Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy.
3/2002	The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gillian M Tozer Research Topics

Disease

35	Neoplasms (Cancer) 12/2018 - 03/2002
10	Fibrosarcoma 11/2017 - 04/2008
8	Necrosis 04/2014 - 02/2002
6	Carcinosarcoma 08/2003 - 04/2002
5	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 04/2002
5	Hypoxia (Hypoxemia) 01/2020 - 07/2002
3	Neoplasm Metastasis (Metastasis) 01/2017 - 07/2004
2	Carcinoma (Carcinomatosis) 04/2002 - 01/2002
1	Adenocarcinoma 01/2017
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 02/2007
1	Prostatic Neoplasms (Prostate Cancer) 02/2007
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2007

Drug/Important Bio-Agent (IBA)

9	combretastatinIBA 01/2020 - 03/2002
9	fosbretabulin (combretastatin A4)IBA 12/2018 - 02/2002
8	Protein Isoforms (Isoforms)IBA 10/2017 - 04/2008
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2017 - 04/2008
6	TubulinIBA 12/2013 - 02/2002
4	Pyruvic Acid (Pyruvate)IBA 01/2022 - 02/2014
4	Pharmaceutical PreparationsIBA 12/2017 - 12/2002
3	Lactic Acid (Lactate)FDA LinkGeneric 01/2022 - 09/2015
3	Proteins (Proteins, Gene)FDA Link 04/2014 - 05/2003
3	iodoantipyrineIBA 06/2009 - 04/2002
2	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 12/2017
2	Adenosine Monophosphate (AMP)IBA 01/2020 - 12/2002
2	Phosphates (Orthophosphate)IBA 12/2018 - 07/2002
2	Oxygen (Dioxygen)IBA 09/2015 - 05/2005
2	Biological ProductsIBA 01/2014 - 01/2010
2	Complementary DNA (cDNA)IBA 01/2012 - 01/2002
2	Nitric Oxide Synthase (NO Synthase)IBA 06/2009 - 02/2007
2	fluorescein isothiocyanate dextranIBA 04/2008 - 01/2008
2	Dextrans (Dextran)FDA Link 01/2008 - 03/2002
2	Contrast MediaIBA 01/2008 - 02/2007
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 02/2007 - 05/2005
2	ProdrugsIBA 04/2005 - 01/2002
2	DNA (Deoxyribonucleic Acid)IBA 11/2004 - 04/2002
2	Green Fluorescent ProteinsIBA 11/2004 - 04/2002
1	Urea (Carbamide)FDA LinkGeneric 01/2022
1	Adenosine Triphosphate (ATP)IBA 01/2020
1	Myosin Light Chains (Myosin Essential Light Chain)IBA 01/2020
1	cadherin 5IBA 01/2020
1	combretastatin A-1IBA 12/2017
1	A-factor (Streptomyces)IBA 12/2017
1	Diphosphates (Pyrophosphates)IBA 12/2017
1	LectinsIBA 11/2017
1	Biomarkers (Surrogate Marker)IBA 01/2017
1	Tumor Viral Antigens (Large T Antigen)IBA 01/2017
1	Doxycycline (Periostat)FDA LinkGeneric 01/2017
1	LigandsIBA 01/2017
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2017
1	Molecular Chaperones (Chaperone, Molecular)IBA 04/2014
1	OxindolesIBA 12/2013
1	Semaxinib (SU5416)IBA 12/2013
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 12/2013
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 12/2013
1	PlectinIBA 11/2013
1	VimentinIBA 11/2013
1	Chemokine CXCL12IBA 05/2011
1	Dendrimers (Dendrons)IBA 03/2010
1	Lysine (L-Lysine)FDA Link 03/2010
1	Protamines (Protamine Sulfate)FDA Link 03/2010
1	Molecular Probes (Molecular Probe)IBA 01/2010
1	Drinking WaterIBA 06/2009
1	Angiogenesis InhibitorsIBA 06/2009
1	Nitroarginine (NG Nitro L Arginine)IBA 06/2009
1	Fluorescein-5-isothiocyanate (FITC)IBA 01/2008
1	isothiocyanic acidIBA 01/2008
1	Fluorescein (Funduscein)FDA LinkGeneric 01/2008
1	Arginine (L-Arginine)FDA Link 02/2007
1	bisbenzimide ethoxide trihydrochloride (Hoechst 33342)IBA 02/2007
1	S-nitrosohemoglobinIBA 05/2005
1	EnzymesIBA 04/2005
1	Cytotoxins (Cytolysins)IBA 04/2005
1	Acetic Acid (Vinegar)FDA LinkGeneric 07/2004
1	indoleIBA 07/2004
1	Horseradish PeroxidaseIBA 07/2004
1	AcidsIBA 07/2004
1	GadoliniumIBA 08/2003
1	Pentetic Acid (DTPA)FDA LinkGeneric 08/2003
1	tin protoporphyrin IXIBA 05/2003
1	BilirubinIBA 05/2003
1	Antipyrine (Phenazone)FDA Link 05/2003
1	copper protoporphyrin IXIBA 05/2003
1	N-acetylcochinol-O-phosphateIBA 12/2002
1	Coloring Agents (Dyes)IBA 12/2002
1	Eosine Yellowish-(YS) (Eosin)IBA 12/2002
1	Hematoxylin (Haematoxylon)IBA 12/2002
1	omega-N-Methylarginine (NG Monomethyl L Arginine)IBA 12/2002
1	N(G)-iminoethylornithineIBA 12/2002

Therapy/Procedure

13	Therapeutics 01/2020 - 07/2003
3	Aftercare (After-Treatment) 05/2011 - 12/2002
2	Lasers (Laser) 06/2009 - 05/2005
1	Intravenous Administration 01/2022
1	Intravenous Infusions 12/2017
1	Intra-Arterial Infusions 12/2017
1	Intravenous Injections 01/2017
1	Cannula 02/2014
1	Injections 02/2014
1	Precision Medicine 03/2010
1	Radioimmunotherapy 02/2007
1	Radiotherapy 07/2004